DB:0OP

Stock Analysis Report

Executive Summary

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States.


Snowflake Analysis

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has OptiNose's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 0OP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

13.6%

0OP

-1.7%

DE Pharmaceuticals

-0.9%

DE Market


1 Year Return

9.2%

0OP

17.5%

DE Pharmaceuticals

12.8%

DE Market

Return vs Industry: 0OP underperformed the German Pharmaceuticals industry which returned 17.5% over the past year.

Return vs Market: 0OP underperformed the German Market which returned 12.8% over the past year.


Shareholder returns

0OPIndustryMarket
7 Day13.6%-1.7%-0.9%
30 Day-10.7%0.6%-0.4%
90 Day-15.5%9.9%2.3%
1 Year9.2%9.2%21.6%17.5%16.3%12.8%
3 Yearn/a40.4%24.5%15.8%5.7%
5 Yearn/a38.1%14.6%19.7%3.3%

Price Volatility Vs. Market

How volatile is OptiNose's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is OptiNose undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 0OP (€7.1) is trading below our estimate of fair value (€87.1)

Significantly Below Fair Value: 0OP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 0OP is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: 0OP is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 0OP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 0OP is overvalued based on its PB Ratio (7x) compared to the DE Pharmaceuticals industry average (2.3x).


Next Steps

Future Growth

How is OptiNose forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

60.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0OP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: 0OP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 0OP's is expected to become profitable in the next 3 years.

Revenue vs Market: 0OP's revenue (41.4% per year) is forecast to grow faster than the German market (5.2% per year).

High Growth Revenue: 0OP's revenue (41.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 0OP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has OptiNose performed over the past 5 years?

-45.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 0OP is currently unprofitable.

Growing Profit Margin: 0OP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 0OP is unprofitable, and losses have increased over the past 5 years at a rate of -45.7% per year.

Accelerating Growth: Unable to compare 0OP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0OP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.3%).


Return on Equity

High ROE: 0OP has a negative Return on Equity (-250.32%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is OptiNose's financial position?


Financial Position Analysis

Short Term Liabilities: 0OP's short term assets ($144.1M) exceed its short term liabilities ($30.0M).

Long Term Liabilities: 0OP's short term assets ($144.1M) exceed its long term liabilities ($74.9M).


Debt to Equity History and Analysis

Debt Level: 0OP's debt to equity ratio (166.8%) is considered high.

Reducing Debt: Insufficient data to determine if 0OP's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 0OP has a low level of unsold assets or inventory.

Debt Coverage by Assets: 0OP's debt is covered by short term assets (assets are 1.9x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 0OP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 0OP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is OptiNose's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 0OP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 0OP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 0OP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 0OP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 0OP's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Peter Miller (58yo)

10.1yrs

Tenure

US$778,601

Compensation

Mr. Peter K. Miller has been the Chief Executive Officer of OptiNose US Inc., since 2010. Mr. Miller has been the Chief Executive Officer at Optinose, Inc. since 2010. He serves as the Chief Executive Offi ...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD778.60K) is about average for companies of similar size in the German market ($USD802.74K).

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Peter Miller
CEO & Director10.1yrsUS$778.60k0.29% $910.0k
Ramy Mahmoud
President & COO10.1yrsUS$609.00k0.12% $381.9k
Keith Goldan
Chief Financial Officer3.1yrsUS$486.67k0.015% $46.4k
Michael Marino
Chief Legal Officer & Corporate Secretary3.1yrsUS$510.50k0.016% $49.1k
Jonathan Neely
Vice President of Investor Relations & Business Operations0yrsno datano data
Karen Brophy
Vice President of Human Resources2yrsno datano data
John Messina
Senior Vice President of Clinical Development & Medical Affairs2.3yrsno datano data
Victor Clavelli
Chief Commercial Officer0yrsno datano data
Helena Djupesland
Co-Founder of Optinose AS (Norway) & Co-CEO of Optinose AS (Norway)0yrsno datano data

3.1yrs

Average Tenure

54yo

Average Age

Experienced Management: 0OP's management team is considered experienced (3.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Peter Miller
CEO & Director10.1yrsUS$778.60k0.29% $910.0k
William Doyle
Non-Management Director10.1yrsUS$252.01k0.041% $129.1k
Joseph Scodari
Chairman of the Board2.3yrsUS$295.93k0.027% $86.0k
Sandra Helton
Independent Director2yrsUS$597.62kno data
Sriram Venkataraman
Independent Director10.1yrsUS$267.01kno data
Joshua Tamaroff
Non-Management Director2.9yrsUS$257.01kno data
Wilhelmus C. Groenhuysen
Independent Director2.3yrsUS$263.71kno data
Robert O'Neil
Independent Director1.7yrsUS$448.69k0.0044% $13.7k

2.6yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 0OP's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 0OP insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.5%.


Top Shareholders

Company Information

OptiNose, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OptiNose, Inc.
  • Ticker: 0OP
  • Exchange: DB
  • Founded: 2010
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$341.979m
  • Listing Market Cap: US$314.826m
  • Shares outstanding: 45.84m
  • Website: https://www.optinose.com

Number of Employees


Location

  • OptiNose, Inc.
  • 1020 Stony Hill Road
  • Suite 300
  • Yardley
  • Pennsylvania
  • 19067
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OPTNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2017
0OPDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2017

Biography

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. It has a license agreement with Inexia Limited to manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 23:01
End of Day Share Price2020/02/21 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.